Clinical Trial Update: A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque [Phase 3]

View source ↗

Summary

Phase 3 CCTA imaging trial evaluating the effect of obicetrapib in combination with ezetimibe on coronary plaque; currently ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Coronary Artery Disease
• Hyperlipidemia

Drugs mentioned

• EZETIMIBE (EZETIMIBE)
• Obicetrapib (obicetrapib)

Snippet

Sponsor: NewAmsterdam Pharma | Conditions: Lipidemia, Coronary Artery Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING